Non-canonical BRAF mutations and AML treatment response
Official title: Non-canonical BRAF mutations in AML development and therapeutic response
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11446039 · Data updated 2026-11-12
This project looks at how unusual BRAF gene mutations affect how acute myeloid leukemia behaves and responds to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | July 20, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $522,196 |
| NIH project number | 1R01CA306913-01A1 |
| Project ID | NIH-11446039 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older with AML, especially those whose leukemia harbors noncanonical BRAF mutations, may be eligible or benefit from related future studies.
✕Less likely to help
Patients without BRAF mutations or those not matching the trial-eligible criteria may not directly benefit from this research.
What this research studies
Researchers will use genetically engineered mouse models and patient-derived tumor samples to study noncanonical BRAF mutations found in AML. By mapping how these mutations alter the RAS/MAPK/ERK signaling pathway, the team aims to understand why some AML therapies may fail in patients with these mutations. The study will combine modern genetic models with clinical samples to identify potential new approaches for overcoming therapeutic resistance in AML. The goal is to translate these insights into strategies that could improve treatment responses for adults living with AML.
Why it matters
Potential benefit: If successful, the work could lead to better-tailored therapies for AML patients with BRAF mutations and reduced risk of relapse.
How similar studies have gone: Preclinical models and patient-derived samples have shown that targeting BRAF-related pathways can influence AML behavior, though results with noncanonical mutations are still emerging.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Miles, Linde a — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Miles, Linde a
Related research
Other NIH-funded projects on the same topics.
-
Accelerating Rheumatic Heart Disease Prevention in Uganda
A program to find people with rheumatic heart disease in Ugandan communities and give them preventive care close to home.
-
Enhanced surveillance network to track childhood vaccines and viral infections in kids
A nationwide pediatric surveillance network will closely watch how common viruses and vaccines affect children’s health, using standard protocols at hospital and ED sites.
-
Advancing CNS drug delivery through epigenetic tweaks
A medical research project aims to help people with lysosomal storage disorders by improving how treatments reach the brain.
-
Spina Bifida Registry for Better Clinic Care
A national registry project aims to improve care for people with spina bifida by collecting and sharing data from multidisciplinary clinics to guide evidence-based practices.
-
Hydroxyurea to help children with sickle cell anemia in Africa
A pediatric study tests hydroxyurea treatment for young children with sickle cell anemia in several African countries to see if it can reduce illness and improve health.
-
Hydroxyurea for Children with Sickle Cell in Africa
A pilot study tests hydroxyurea in young children with sickle cell disease across several African countries to see if it can reduce illness and hospital visits.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.